Preoperative and adjuvant treatment of localized rectal cancer

Current Oncology Reports

Volumn 8, Issue 3, 2006, Pages 167-173

  Das, Prajnan ^a   Crane, Christopher H ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ANUS SPHINCTER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; HUMAN; PATHOLOGY; POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RECTUM CANCER; RECTUM RESECTION; REVIEW; STANDARDIZATION; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT;

ANTICARCINOGENIC AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; FLUOROURACIL; HUMANS; MEDICAL ONCOLOGY; PREOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; SURVIVAL;

EID: 33646253915     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0016-6     Document Type: Review

References (46)

1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Anonymous: Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985, 312:1465-1472.
3. Douglass HO Jr, Moertel CG, Mayer RJ, et al.: Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986, 315:1294-1295.
4. Krook JE, Moertel CG, Gunderson LL, et al.: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991, 324:709-715.
5. Wolmark N, Wieand HS, Hyams DM, et al.: Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000, 92:388-396.
6. O Connell M, Martenson JA, Wieand HS, et al.: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331:502-507.
7. Sauer R, Becker H, Hohenberger W, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
8. Bosset JF, Calais G, Mineur L, et al.: Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results: EORTC 22921. J Clin Oncol 2005, 23:5620-5627.
9. Bosset J, Calais G, Mineur L, et al.: Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial. J Clin Oncol 2005, 23:247s.
10. Gerard J, Romestaing P, Bonnetain F, et al.: Preoperative chemoradiotherapy (CT-RT) improves local control in T3-4 rectal cancers: Results of the FFCD 9203 randomised trial. Int J Radiat Oncol Biol Phys 2005, 63:S2.
11. Folkesson J, Birgisson H, Pahlman L, et al.: Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005, 23:5644-5650.
12. Bujko K, Nowacki MP, Kepka L, et al.: Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs chemoradiation. Colorectal Dis 2005, 7:410-416.
13. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al.: Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004, 72:15-24.
14. Fisher B, Wolmark N, Rockette H, et al.: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988, 80:21-29.
15. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
16. Dunst J, Reese T, Sutter T, et al.: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002, 20:3983-3991.
17. Jin J, Li YX, Liu YP, et al.: A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys 2006, 64:725-729.
18. Ngan SY, Michael M, Mackay J, et al.: A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 2004, 91:1019-1024.
19. De Paoli A, Chiara S, Luppi G, et al.: Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006, 17:246-251.
20. Kim JC, Kim TW, Kim JH, et al.: Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2005, 63:346-353.
21. Lin EH, Skibber J, Delclos M, et al.: A phase II study of capecitabine and comcomitant boost radiaotherapy in patients with locally advanced rectal cancer. J Clin Oncol 2005, 23:269s.
22. Das P, Lin EH, Bhatia S, et al.: Neoadjuvant chemoradiation with capecitabine versus infusional 5-fluorouracil (5-FU) for locally advanced rectal cancer: a matched pair analysis. Int J Radiat Oncol Biol Phys 2005, 63:S164.
23. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
24. O'Connell MJ, Wolmark N, Beart R, et al.: Update on design of the National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2005, 23:933-934.
25. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
26. Kabbinavar FF, Hambleton J, Mass RD, et al.: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
27. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005,23:1s.
28. Willett CG, Boucher Y, di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
29. Willett CG, Boucher Y, Duda DG, et al.: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
30. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
31. Janjan NA, Crane C, Feig BW, et al.: Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001, 24:107-112.
32. Rodel C, Martus P, Papadoupolos T, et al.: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-8696.
33. Vecchio FM, Valentini V, Minsky BD, et al.: The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005, 62:752-760.
34. Gunderson LL, Sargent DJ, Tepper JE, et al.: Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004, 22:1785-1796.
35. Das P, Skibber J, Rodriguez-Bigas M, et al.: Clinical and pathologic predictors of locoregional recurrence (LR), distant metastasis (DM) and overall survival (OS) in patients treated with chemoradiation and mesorectal excision for locally advanced rectal cancer. J Clin Oncol 2005, 23:270s.
36. Mawdsley S, Glynne-Jones R, Grainger J, et al.: Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 2005, 63:745-752.
37. Peeters KC, van de Velde CJ, Leer JW, et al.: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients: a Dutch colorectal cancer group study. J Clin Oncol 2005, 23:6199-6206.
38. Birgisson H, Pahlman L, Gunnarsson U, et al.: Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005, 23:6126-6131.
39. Sebag-Montefiore D, Glynne-Jones R, Falk S, et al.: A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer 2005, 93:993-998.
40. Francois E, Ychou M, Ducreux M, et al.: Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: A phase I study. Eur J Cancer 2005, 41:2861-2867.
41. Aschele C, Friso ML, Pucciarelli S, et al.: A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005, 16:1140-1146.
42. Rodel C, Grabenbauer GG, Papadopoulos T, et al.: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003, 21:3098-3104.
43. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, et al.: A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006, 17:50-56.
44. Machiels JP, Duck L, Honhon B, et al.: Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOx-Cape study. Ann Oncol 2005, 16:1898-1905.
45. Klautke G, Feyerherd F, Ludwig K, et al.: Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer 2005, 92:1215-1220.
46. Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, et al.: Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005, 23:1350-1357.